News Headlines Article

Why this pain-killing opioid is spinning into a new company
San Francisco Business Times

Three months ahead of a regulatory decision on its pain-killing opioid, Nektar Therapeutics Inc. spun the drug into a wholly owned subsidiary.

Inheris Biopharma Inc. also will adopt several preclinical central nervous system assets that it will lead into development, San Francisco-based Nektar (NASDAQ: NKTR) said Thursday.